Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
The current literature suggests that the mode of action of benralizumab is to deplete eosinophils through a mechanism of antibody-dependent cell-mediated cytotoxicity. This direct cellular cytotoxicity may not explain all of the benralizumab effects. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.
Epistemonikos ID: a0a938667a98dd7ef90aa99d1d3a52a7cfeb4daa
First added on: May 10, 2024